Advanced Medical Research

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Lupus (SLE)5 trials
• Sjögren's disease3 trials
• Psoriasis1 trial
• Psoriatic arthritis1 trial
• Rheumatoid arthritis1 trial

Phase

• Phase 37 trials
• Phase 21 trial

Status

• Active, not recruiting6 trials
• Recruiting2 trials

Lead sponsor

• Novartis Pharmaceuticals6 trials
• Janssen Research & Development, LLC2 trials

Running trials

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

  NCT06293365· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

  NCT06133972· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Reza Azadegan

• Active, not recruiting

  A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

  NCT05985915· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

  NCT05624749· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

  NCT05349214· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

  NCT05126277· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Active Psoriatic Arthritis

  NCT04882098· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lupus (SLE)2 recruiting